Fused pyrimidine compounds acting as menin (MEN1)/MLL interaction inhibitors have been described in a Biomea Fusion Inc. patent and reported to be useful for the treatment of cancer, osteoporosis, autoimmune and inflammatory diseases, among others.

Ankh Life Sciences Ltd. have identified polycyclic compounds reported to be useful for the treatment of bacterial, fungal and viral infection.

Eli Lilly & Co. has patented new cyclic GMP-AMP synthase (MB21D1; cGAS) inhibitors reported to be useful for the treatment of Aicardi-Goutieres syndrome, dermatomyositis, systemic lupus erythematosus and lupus nephritis.

Aeovian Pharmaceuticals Inc. has disclosed new ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 (CD38) inhibitors reported to be useful for the treatment of neurodegenerative diseases.

Ono Pharmaceutical Co. Ltd. has entered into a discovery collaboration agreement with Evqlv Inc. to generate novel antibodies against multiple targets selected by Ono, for the development of innovative antibody drugs.

Olix Pharmaceuticals Inc. has received approval from the Alfred Human Research Ethics Committee (HREC) in Australia to conduct a phase I clinical trial of drug candidate OLX-75016 for the treatment of nonalcoholic steatohepatitis (NASH).

PI3Kα H1047R accounts for one-third of all PI3Kα mutations and is associated with treatment resistance to targeted therapies in breast cancer treatment. In addition, treatment with selective PI3Kα inhibitors often results in significant adverse events such as hyperglycemia due to on-target toxicity.

Researchers from Bridgebio Pharma Inc. recently presented BBO-10203, a first-in-class, orally bioavailable, covalent small-molecule candidate designed to inhibit RAS-driven PI3Kα activity without affecting glucose metabolism.